A life-extending prostate cancer drug will continue to only be available to sufferers who have already undergone chemotherapy, the NHS financial watchdog said.
In final draft guidance reassessing the use in the NHS in England of abiraterone, the National Institute for Health and Care Excellence (Nice) ruled that to extend the availability of the drug was "not cost effective at its current price."
There is "clear evidence" that the use of abiraterone before chemotherapy gives patients "longer healthier lives," according to The Institute of Cancer Research, where the drug was discovered.
Nice's chief executive Sir Andrew Dillion said: "We know how important it is for patient to have the option to delay chemotherapy and its associated side affects, so we are disappointed not to be able to recommend abiraterone for use in this way.
"However, the manufacturer's own economic model demonstrated that the drug does not offer enough benefit to justify its price."
More top news
A lawyer representing 35 families who lost loved-ones when a pilot deliberately crashed his plane 'can't explain' €25,000 offer.
Visitors were evacuated from a rollercoaster at Alton Towers after a power cut forced the ride to grind to a halt.
A town centre water fountain is under threat after repeated attacks by 'bubble vandals', costing hundreds of pounds to repair and clean.